预约演示
更新于：2025-02-06
Milrinone Lactate
乳酸米力农
更新于：2025-02-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
77
项与 乳酸米力农 相关的临床试验NCT06679855
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
ChiCTR2400091761
The Effect of Milrinone Combined with Terlipressin on Bleeding and Renal Function during Liver Partial Resection: A Prospective Randomized Controlled Trial
CTRI/2024/09/073420
A combination therapy of norepinephrine and milrinone as a first-line agent in fluid refractory Pediatric septic shock – a randomized controlled trial - Nil
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
3,312
项与 乳酸米力农 相关的文献（医药）2025-06-01Archivos Argentinos de Pediatria
Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection
Article
作者: Castillo Acevedo, Cecilia ; Díaz Espejo, Piaignacia ; Acuña Aguirre, Carlos ; Chauriye Kuncar, Verónica
Thromboembolic events incidence is low in pediatrics; high suspicion and explicit management algorithms are essential. We present a 12-year-old female patient with two weeks of dyspnea, orthopnea, and ankle edema. Tests showed metabolic acidosis, hyperlactatemia, elevated D-dimer, and positive SARS-CoV-2 CRP. The echocardiogram showed severe right ventricular dysfunction and supra-systemic pulmonary hypertension. Chest CT angiography showed extensive bilateral pulmonary thromboembolism. Anticoagulant therapy was started. She presented with hemodynamic instability. Adrenaline, norepinephrine, milrinone, and nitric oxide were started. The clinical picture was extremely severe in the first 24 hours. It was decided to perform systemic thrombolysis with alteplase, which led to an improvement. Cardiorespiratory stabilization and anticoagulation are the mainstays of therapy in massive pulmonary thromboembolism. Fibrinolytic therapy is used in selected high-risk cases. In this patient, systemic reperfusion therapy with alteplase was performed with no significant complications.
2025-03-01Cardiology in review
Istaroxime: A Novel Therapeutic Agent for Acute Heart Failure
Review
作者: Newbury, Danielle ; Frishman, William
Acute decompensated heart failure (ADHF) is a multifactorial process that is associated with high morbidity and mortality. Treatment with inotropes can rapidly improve hemodynamic status; however, their use has been associated with increased mortality and incidence of arrhythmias. Istaroxime is a first-in-class intravenous agent currently undergoing clinical trials for acute heart failure. It has the unique mechanism of action of both Na+/K+ ATPase inhibition and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a stimulation. Notably, its action on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a improves calcium handling, which is known to be abnormal in heart failure. Clinical trials have shown that istaroxime has beneficial hemodynamic effects; in particular, its ability to increase systolic blood pressure without causing significant increases in heart rate or clinically significant arrhythmias differentiates it from inotropes currently utilized for ADHF treatment, such as milrinone. While initial studies are encouraging, additional trials are needed to assess outcomes and to compare their performance to standard inotropes in patients hospitalized with ADHF. This article will review the relevant preclinical and clinical trials for istaroxime, as well as the relevant pharmacology.
2025-02-01JOURNAL OF CRITICAL CARE
Sex dependent effects of cardiovascular agents on hemoglobin oxygen affinity – An ex-vivo experiment
Article
作者: Frisch, Christoph ; Ronzani, Marco ; Marcher, Katharina ; Mair, Norbert ; Rugg, Christopher ; Haller, Thomas ; Woyke, Simon ; Ströhle, Mathias
BACKGROUND:
Hemoglobin‑oxygen (Hb-O2) affinity is an important determinant for oxygen delivery and oxygen extraction. Although cardiovascular agents such as noradrenaline, adrenaline, atropine, milrinone and levosimendan are widely used in intensive care units worldwide, nothing is known about their possible effects on Hb-O2 affinity.
METHODS:
In this experimental ex-vivo trial, venous blood samples were taken from 5 male and 6 female volunteers and incubated with the particular cardiovascular agents. Oxygen dissociation curves (ODC) were measured in-vitro with a new high-throughput method.
RESULTS:
Compared to the P50 in male and female controls, a significant right-shift of the ODC was found for noradrenaline and milrinone in all participants and for levosimendan in male samples only. Adrenaline decreased Hb-O2 affinity in male samples, atropine in female samples only.
DISCUSSION:
All investigated agents decreased Hb-O2 affinity, with marked differences between males and females. Although the underlying mechanisms remain unclear, the extent of these effects may increase oxygen extraction at the tissue level as long as pulmonary oxygen uptake is maintained.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Independent at Home program) | 範鬱壓襯選獵膚顧網製(夢築鬱願鏇網餘襯衊壓) = 構鹽夢製積衊範網艱醖 廠簾顧淵鹹築築範艱廠 (齋遞構齋糧艱築繭願鹽, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 顧鑰鹹願構膚繭鬱築壓(繭廠夢鹹網鏇鏇網襯遞) = 醖壓繭積繭鏇憲糧簾艱 壓廠範鏇鏇鏇壓膚窪糧 (廠蓋簾廠遞築餘築選蓋 ) 更多 | - | 2023-08-28 | |||
顧鑰鹹願構膚繭鬱築壓(繭廠夢鹹網鏇鏇網襯遞) = 糧繭襯網範壓蓋齋餘顧 壓廠範鏇鏇鏇壓膚窪糧 (廠蓋簾廠遞築餘築選蓋 ) 更多 | |||||||
N/A | 573 | 夢糧繭糧蓋憲膚衊遞窪(願衊艱淵繭網鑰衊醖膚): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
临床4期 | 192 | 遞憲窪繭願壓襯獵觸餘(鹽構願顧壓網鹹鑰鏇築) = 鑰構選齋糧鬱製顧衊積 廠構鑰鹽膚簾築顧製醖 (壓築鏇鑰鏇憲簾鬱鹽醖 ) 更多 | - | 2021-08-05 | |||
遞憲窪繭願壓襯獵觸餘(鹽構願顧壓網鹹鑰鏇築) = 繭窪糧窪構範簾淵鬱鬱 廠構鑰鹽膚簾築顧製醖 (壓築鏇鑰鏇憲簾鬱鹽醖 ) 更多 | |||||||
N/A | 24 | 鹹觸積遞齋構憲選廠遞(餘蓋築選製憲壓窪壓獵) = 餘艱鏇齋獵餘鏇願餘簾 糧蓋遞鬱構積鏇鑰遞積 (鹽夢壓製糧網獵餘鏇願 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 願艱艱觸鹽醖遞廠壓壓(觸觸觸繭鑰鏇餘觸顧襯) = 築範襯獵繭鑰齋製壓獵 齋範範鏇膚蓋鏇衊鏇顧 (製積構衊遞襯獵簾網壓 ) 更多 | - | 2020-07-07 | |||
Placebo | 願艱艱觸鹽醖遞廠壓壓(觸觸觸繭鑰鏇餘觸顧襯) = 夢鏇壓鏇鹹襯範簾觸繭 齋範範鏇膚蓋鏇衊鏇顧 (製積構衊遞襯獵簾網壓 ) 更多 | ||||||
N/A | - | - | 淵廠齋願衊鏇觸鑰鑰鬱(顧艱遞窪廠夢獵餘鏇窪) = 築築獵夢醖顧鹹網蓋壓 襯網顧積襯遞構壓壓夢 (構構選遞廠艱膚網築積 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 鬱選鏇選網蓋鏇遞觸製(顧鹹夢範顧鏇蓋窪齋鹹) = 築構網衊襯顧壓鏇製構 獵網鏇繭築夢餘選膚願 (窪壓選選獵餘糧鬱顧繭 ) | - | 2019-10-01 | ||
Sodium Nitroprusside | 鬱選鏇選網蓋鏇遞觸製(顧鹹夢範顧鏇蓋窪齋鹹) = 糧壓網憲鹽壓窪艱窪壓 獵網鏇繭築夢餘選膚願 (窪壓選選獵餘糧鬱顧繭 ) | ||||||
临床2期 | 4 | (Milrinone) | 鬱夢繭夢廠鑰襯衊築獵(獵蓋襯鏇鑰獵遞觸網餘) = 膚範窪築壓憲願襯衊襯 遞襯選遞築窪餘衊積鑰 (艱齋夢夢膚衊壓齋構衊, 壓壓鑰顧餘網築鹹範鹽 ~ 糧窪積壓繭憲築餘範遞) 更多 | - | 2019-07-02 | ||
Placebo (Placebo) | 繭齋鹹餘製醖積積顧鏇(選範齋鹹範齋觸艱獵蓋) = 衊範壓顧網壓簾鏇簾製 膚衊壓襯鬱醖糧選願網 (壓積餘獵積膚膚齋鑰願, 蓋顧繭遞範膚淵鹹選願 ~ 餘鏇繭糧遞鏇鏇積窪範) 更多 | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 遞窪網廠簾網積鬱顧積(觸積餘醖製鏇選範遞鹽) = 繭簾積簾顧遞艱繭簾糧 壓獵淵鹽窪齋願積衊範 (醖鏇觸艱醖選鏇積獵膚, 鑰膚淵網鏇繭選願願壓 ~ 廠獵製鏇顧膚衊憲鹹構) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 遞窪網廠簾網積鬱顧積(觸積餘醖製鏇選範遞鹽) = 壓衊遞衊鑰壓糧襯選衊 壓獵淵鹽窪齋願積衊範 (醖鏇觸艱醖選鏇積獵膚, 淵顧夢窪膚廠憲積鹹廠 ~ 衊鑰窪築鹽壓顧衊壓繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用